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  1Abstract. 
 
This paper differs in two ways from previous comparative health system 
research.  First, it focuses on the impact of pharmaceutical expenditures on total health 
expenditures as trends in pharmaceutical expenditures have been blamed of being a 
major driver of national health expenditures. In addition to pharmaceutical 
expenditures, other variables of interest are income, public financing, public delivery, 
ageing and urbanization. Second, the analysis includes a thorough sensitivity analysis 
on the proposed model using four samples (with and without the US, and imputed and 
not imputed data) to address the issue of robustness.   
Based on a typology of health care systems, trends of relevant explanatory 
variables are described using OECD Health Data 2003 data. Unlike any other of the 
variables, pharmaceutical expenditures show contradicting trends when measured as 
per capita pharmaceutical expenditures and pharmaceutical share of total health 
expenditures.   
Next, a regression analysis is performed on data from 1970 – 2000 for 19 OECD 
countries.  Regression diagnostics indicated the absence of multicollinearity but the 
presence of heteroscedasticity and autocorrelation.  Based on the Hausman test, a 
fixed effect model was chosen. As in all previous empirical research, per capita GDP 
turned out to be the most influential explanatory variable.  While public financing of 
health care was always three out of four samples significantly inversely related to 
health expenditures, public delivery   as a NHS dummy was always significantly 
positively related to the dependent variable. Unlike previous research, ageing is 
consistently and significantly related to higher total health expenditures and, so is 
urbanization.  Finally, all samples show a highly negative relationship between share 
of pharmaceutical expenditures and health expenditures, suggesting support for the 
substitution theory.  
 
 
Keywords: health care expenditure, health care system, health economics, health 
policy, comparative. 
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Introduction. 
 
  The body of quantitative comparative health system literature has mainly focused on 
the impact of income and to a lesser degree the source of financing on total per capita 
health expenditures.  This does not come as a surprise since both variables and 
especially income explain most of the variance of total per capita health expenditures.   
      This paper has two purposes.  On the one hand, besides demographic control 
variables, attention is given to two explanatory variables that have not often been 
included in empirical models.  A first explanatory variable is the share of total health 
expenditures spent on pharmaceuticals.  The reason for including this variable in the 
model is the pattern it shows over the last thirty years as described in the next session 
as well as the its blameworthiness for the ever increasing total national health 
expenditures.  A proxy variable representing the public delivery of medical care is also 
introduced in the model to complement the variable that measures the publicness of 
health care financing (figure 1). On the other hand, the proposed model’s robustness is 
tested with four different samples.  One sample is based on imputed date and the other 
sample is based on non-imputed data.  For both samples, the analysis is done with and 
without the United States.  The reason is that the United States’ health care system can 
be considered to be so different than any other health care system vis-à-vis its total per 
capita health expenditures. 
 
 
Trends in Pharmaceutical Expenditures. 
 
   Pharmaceutical  expenditures  as  a  percent of total health expenditure show a 
decreasing trend from 1970 to the mid-eighties after which they started to increase 
again (Figure 2).  The United States’ share of pharmaceutical expenditures is lower 
than the other two types of health care systems. In the United States, while 
experiencing a steady decrease of pharmaceutical share of total health expenditures 
from 12.4 % in 1970 to 8.6% in 1994, a steep increase took place from 1995 to 8.9% 
to 11.9% of total health expenditures.     
  Per capita spending on per capita pharmaceutical expenditures ($ PPP) increased 
steadily from 1970 to 2000 for all types of health care systems (Figure 3).  In 1970, 
compared to the United States with $ 159 per capita pharmaceutical expenditures, 
countries without a NHS spent $ 119.4 per capita, while NHS countries spent the 
lowest per capita on pharmaceuticals with $ 18.5 per capita.  Ten years later in 1980, 
per capita spending on health expenditures has doubled. This doubling trend has 






Total health expenditures and income. 
 
      Simple regression analysis on cross sectional as well as pooled time series has 
shown that GDP per capita explains a substantial percent of variation of total per 
capita health expenditures independent of whether exchange rates or purchasing power 
parities (PPPs) are used. (Newhouse, 1977; OECD, 1987; Parkin, et.al., 1987; Parkin, 
et.al., 1989; Hitiris & Posnett, 1992; O’Connel, 1996). 
  3   Similar results with respect to GDP have been obtained in multivariate cross section 
and time series analyses.  Kleiman’s (1974) seminal cross sectional multivariate 
analysis established that GDP in terms of exchange rates was significantly and 
positively related to total health expenditures in all models tested.  This was confirmed 
by later cross sectional analysis using exchange rates (OECD, 1985; Leu, 1986, 
Getzen, 1992; Gerdtham & Jönsson, 1991) and PPPs (OECD, 1985; Pfaff, 1990; 
Gerdtham & Jönsson, 1991; Gerdtham et. al., 1992, Getzen 1992; Murillo et.al., 
1993).   
   Multivariate time series analysis has yielded less stable results.  Pfaff (1990) using 
data for three countries confirmed the positive relationship between GDP and total per 
capita health expenditures for Canada and the United States but not for Germany 
where the relationship became negative but not significant.  Kanavos and 
Yfantopoulos (1999) found that GDP had no significant explanatory power in 7 of the 
14 countries of the European Union independent of measurement in terms of exchange 
rates, PPPs or national currencies.  
   For more than a decade, pooled cross section time series multivariate analysis is the 
predominant way to analyze the determinants of health expenditures.  Gerdtham 
(1992) using five pooling methods on a static equilibrium model as well as a dynamic 
error correction model for 22 countries covering 16 years (1972 – 1987) found that for 
both types of models GDP per capita PPP and per capita health expenditures were 
positively and significantly related.  In a follow up study of 22 countries from 1971 
through 1991 (Gerdtham et al. 1994, 1998; Gerdtham, 2003) the effects of GDP on 
total health expenditures were confirmed.  Roberts (1999) using data of a selection of 
20 OECD countries from 1966 to 1993 also obtained a significant positive estimate for 
per capita GDP.    
 
   In other words, studies investigating the determinants of total health expenditures 
have found a significant and positive relationship between per capita GDP and total 
per capita health expenditures, independent of the measurement of GDP, the 
functional form of the empirical model, the type of data (cross-sectional or pooled) 
and whether using simple or multivariate analyses.    
 
 
Pharmaceutical share and total health expenditures. 
 
   With respect to pharmaceutical expenditures, two theories with support of empirical 
findings on a less aggregate exist.  On the one hand, the argument is that 
pharmaceutical expenditures are becoming an increasingly important part of total 
health expenditures due to increased prices of pharmaceutical products and increased 
volume of consumption, together with growth in insurance coverage of prescription 
drugs and increased direct-to-consumer advertisement. (Du Bois et al., 2000; Berndt, 
2001; Reinhardt, 2001; Danzon & Pauly, 2002).  Therefore, pharmaceutical 
expenditures are related to increased health expenditures. 
      On the other hand, an alternative view suggests that in the end many 
pharmaceuticals are more cost-effective than other medical interventions such as 
surgery.  In other words, drugs and especially newer more costly drugs cause 
pharmacoeconomic benefits that offset other medical costs. (Goldberg, 1993; Kleinke, 
2000; Neumann et al. 2000; Soumerai, 2004).  
   Given the limited availibility of emperical results at an aggregate level, no direction 
is predicted with respect to the relationship between share of pharmaceutical 
expenditures and total health expenditures.  As such the goal is to verify which – if 
any – of the above mentioned theories are supported at an aggregate level.   
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The public nature of a health care system. 
 
      First, public expenditures as a share of total health expenditures have been 
introduced in several multivariate analyses.  In the OECD (1985) cross sectional 
models covering 20 countries in three separate years (1970, 1976 and 1980) public 
financing is never significant but is consistently inversely related to total per capita 
health expenditures regardless of functional form or whether expenditures are 
measured in terms of exchange rates or percent of GDP spent on health.   
   In the same OECD study, public financing becomes significant and has a negative 
sign when the three samples are pooled.  Similar results the OECD study were 
obtained by Gerdtham et al. (1992) with 1987 data for 19 countries and.  When using 
pooled data for 22 countries from 1972 through 1992 (Gerdtham, 1992), the sign was 
always negative but significance depended on the statistical method used.  O’Connell 
(1996) also found a significant and inverse relationship between public share of total 
per capita health expenditures for a different sample of 21 countries from 1975 
through 1990.  In Roberts’ (1999) analysis using a sample of 20 countries from 1960 
through 1993, significance of the public share estimates were always positive but 
significance depended upon the statistical method used.  Finally, in Gerdtham et al. 
(1994) negative but insignificant estimates were obtained for public share in a sample 
of 24 countries from 1970 to 1991.  Later, a follow up study by Gerdtham et al. (1998; 
2000) using four different samples only resulted in negative and significant public 
share estimates for sample containing data on 17 countries from 1970 to 1991.  For the 
same sample from 1981 to 1991 and a sample of 22 countries from 1981 to 1991 
estimates were positive but not significant.  
   In other words, unlike per capita GDP, the public share of total health expenditures 
has produced less consistent results.  Both direction and significance depend on the 
sample.  In addition, different statistical methods also produce different estimates in 
terms of sign and significance.   
 
 
Public delivery and health expenditures. 
 
      Leu (1984) found that countries with a public integrated health care system 
(National Health Service) have significantly lower health expenditures than those who 
had not.  Later on, Gerdtham et al. (1992) could not replicate these results.  When 
included in the model with public share of total health expenditures the parameter 
estimate for public integrated health care system became insignificant and, when 
entered in the model with public hospitals and public financing share, the sign of 
public integrated health care system switches directions.  While significantly affecting 
total health expenditures inversely in the follow up study (Gerdtham et al. 1994), this 
result became insignificant in later studies (Gerdtham et al. 1998, 2003). 
  The health system effect is measured through a dummy variable for whether or not a 
country has a National Health Service that is characterized by predominant public 
financing as well as public provision.  As such, this variable also measures the 
predominant nature of the provision of health services in addition to the source of 
financing measured by public share of total health expenditure.    
  As far as this variable actually captures the public provision, the public choice 
argument in the tradition of Buchanan (1969) and Niskanen (1971, 1983) as Leu 
suggests may hold strong. The major reason why government can fail is the absence of 
a link between the costs of producing and the revenues generated for the production of 
the good.  The inability of linking both will encourage inefficiencies and may result in 
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government is likely to fail is embedded in the organizational nature of a nonmarket 
entity.  It refers to internal management problems that have to be overcome on a daily 
basis.  The last economical reason why government can fail is the creation of derived 
externalities.  These unwanted effects come into being through policy measures. 
(Stevens, 1993; Wolf, 1992; Horn, 1995, Miller, 1995)    
  Therefore, we expect countries with an NHS to be more expensive than countries 
without an NHS.   The NHS dummy variable was coded as unity for country and year 
in which a NHS system was in place similar to Gerdtham et al. (1994, 1998, 2003). 
 
 
Demographics and total health expenditures. 
 
   International comparisons  most commonly use the share of population age 65 and 
older as measure for an ageing population.  One cross-sectional analysis of the OECD 
(1985) found that the percent population age 65 and older had no significant impact on 
total per capita health expenditures and that that there was an inverse relationship 
except for the years 1970 and 1976 where the sign was positive. When using change in 
per capita health expenditure over periods of 5 years, age was inversely related with 
the dependent variable.  Getzen (1992) found a negative but insignificant relationship 
between ageing and total health expenditures.  
   Using pooled time series, positive and significant estimates for the percentage of 
population 65 and older were only obtained by Hitiris & Posnett (1992) and 
O’Connell (1996) while in the OECD study (1985) the only significant parameter 
estimates were negative.  Similar to the OECD results, Barros (1998) for four 10-year 
time periods and Roberts (1999) for a 33 year time span never obtained positive or 
significant estimates.  Finally, Okunade (2004) attained no significant relationship 
between health care expenditure growth in $ PPP and ageing on the short run but did a 
find positive and significant relationship on the long run.   
   Intuitively one may think that aging causes health expenditures to increase in two 
ways.  First, the proportion of population of individuals age 65 and older grows.   
Second, life expectancy is increasing (Fuchs, 1990).  In other words, more people are 
age 65 or older and this group of society is living longer causing health expenditures 
to increase because of increased demand for health services (Cassel. et al., 1992; 
Jacobzone, 2000; Lubitz, J. et al., 2001; Alemayehu, et al., 2004).  This demographic 
change combined with the uneven spread of health care cost in a life cycle is expected 
to have an expenditure lifting effect.  Therefore, we expect that an ageing population 
has an expenditure increasing effect. 
   Urbanization has been entered in empirical models on a regular basis.  There are 
several reasons why the level of urbanization may have an increasing effect of health 
expenditure.  From a public health perspective, contagious diseases may spread faster 
in urban arias because of the high density of cities.  This on its turn can increase the 
use of medical services.  Second, compared to rural areas, urban areas have more 
crime and traffic related injuries leading to a higher use of high cost trauma centers.  
Finally, availability and access is likely to be higher in urban areas.  Therefore, the 
level of urbanization is expected to increase health expenditures (Crémieux, et al., 
1999).  This was confirmed by Leu’s analysis (1984) in which positive estimates for 
the impact of urbanization on total health expenditures were obtained.  However, 
urbanization was always significant.  In Gerdtham’s (1992) replication of Leu’s 
model, urbanization had a negative sign and was never significant.  When introduced 
in his own model, urbanization was significant and inversely related to total health 
expenditures.    
 
  6 Model Specification. 
 
Based on the literature review, total per capita health expenditures can be written as 
the following function 
 




THXP are total per capita health expenditures in $ PPP 
GDP is per capita Gross Domestic Product in $ PPP 
Publicshare is the percent of total health expenditures that is financed publicly 
NHS is a dummy for National Health Service systems 
Pharmashare is the percent of total health expenditures that is spent on        
     pharmaceuticals 
    Age65 is the percent of the population age 65 and older 
Urbanization is the percent of total population living in an urban area as 









   The data used for the analysis come from the OECD health data set 2003 for all 
variables except urbanization, which was retrieved from the Worldbank’s World 
Development Indicators data set 2003. The OECD data set contains information on 30 
countries over a time span of more than forty years.  One variable (level of 
urbanization) comes from the Worldbanks’ WDI 2003 dataset.   
    For this study 19 countries were withheld for the analysis: Australia, Austria, 
Canada, Denmark, Finland, Germany, Greece, Iceland, Ireland, Italy, Japan, 
Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, the United Kingdom 
and the United States.  Some countries were not included either because their 
comparability with the included countries: the Czech Republic, Hungary, Korea, 
Luxembourg, Mexico, Poland, the Slovak Republic and Turkey or, because of lack of 
data for the variables on which the multivariate analysis is based: Belgium, France, 
Switzerland.   
   Data have been transformed into their logs.  Previous research (Parkin et.al., 1987, 
Gerdtham, 1992) has indicated that a double log functional form was preferable above 
any other functional form.  More recently, this finding was confirmed by Gerdtham et 





  While pooling has advantages, it also has disadvantages when using multivariate 
regression analysis.  The combination of cross-sectional and time series data easily 
violates the OLS assumptions.  Besides possible model misspecification, pooled data 
tend to be suffering from autocorrelation and heteroscedasticity (Stimson, 1985; Beck 
et. al., 1993; Beck & Katz, 1995; Hicks, 1996; O’Connel, 1996).  In order to test 
  7whether or not the variance of the error term is constant for all observations the χ
2 
based White (1980) test is used.  With respect to the possibility that in time series the 
current observation of the error term is a function of the previous one, the first order 
autocorrelation Breush-Godfrey test is used (Breush, 1978; Godfrey, 1978).  In order 
to determine presence of multi-collinearity variance inflation and tolerance levels are 
calculated (Table 2).  
      Although no multi-colinearity has been detected (Table 3), the presence of 
heteroscedasticity (White test) and autocorrelation (Godfrey test) indicate that there 
are unmodeled country and time specific effects (Table 4).  In order to solve this 
problem, time and country dummies can be introduced.  Country dummies control for 
country specific differences that are not included in the model and, time specific 
dummies control for time related effects not captured by the model. 
  The next step is to determine whether these country and time specific effects are 
random or fixed.  Random effect models are used when the effect are the result of a 
random selection of units of analysis from a population about which inferences are 
made while fixed effect models are used when inferences are made about the units of 
analysis included in the data only (Jones, 2000).  Here, the selected countries do not 
come from regular random sample but are selected based on the availability of data 
and the comparability of countries.  Therefore, a fixed effect model is the most 
appropriate statistical method.  In addition, previous research (Gerdtham, 1992) has 
tested different statistical approaches on a previous version of the OECD data and, the 
two way fixed effect models yielded the most robust results.  In order to confirm the 
appropriateness of this technique, a Hausman test (1978) for fixed effects was 
performed on all models resulting in significant values meaning that a fixed effect is 
an appropriate method to analyze the models.  The results indicate that a fixed effect 
model is preferred (Table 3). 
 
 
Results and Discussion. 
 
   The model has been tested with different samples and table 3 shows that regardless 
of the sample, all models are highly significant with at least an R
2 of .9912.  While this 
R
2 may be considered alarmingly high, it can be explained by the fact that GDP is 
responsible in all equations for at least 90% of the variation in the dependent variable.  
When comparing the unimputed data with on average 21.8% missing values, all 
estimates of the explanatory variables of the model have the similar size, identical 
signs and are statistically significant with the exception of public share of total health 
expenditures, which is not significant when the United States is included in the 
sample.  Results are very similar in the sample with the linearly imputed data, with the 
exception of the public share that is significant whether or not the United States is 
included.  The results indicate that the model tested is robust and that the United Sates 
is to a certain degree is an outlier but at the same token, it must be mentioned that it is 
not really an influential outlier. 
   With respect to income as measured in terms of per capita GDP, all samples yield 
positive estimates of the same magnitude.  Unlike most previous aggregate research 
results and more in the line of the results of meso and micro studies, the results of this 
analysis show an elasticity lower than unity meaning that health car is not a luxury 
good. 
   The wide spectrum of results with respect to the nature of health care as a good is 
caused by two reasons.  First, the wide variety of results can be explained the different 
statistical analysis used to determine the elasticity of health care.  (Kanavos & 
Mossialos, 1999)  A second reason is related to the level of analysis. (Kavanos & 
  8 Mossialos, 1999; Getzen, 2000)  In contrast to aggregate studies, household surveys 
show that health care is a necessity good.  The reason for these rather contradictory 
results is twofold.  On the one hand, micro studies investigate the behavior of 
individuals and make inferences about the average individual while the macro studies 
concentrate on the average behavior of a pool of individuals.  On the other hand, at the 
different levels of analysis, the income effect is experienced in a different way because 
of the level where the budget restrictions take place.   At the micro level, the average 
individuals are much more sensitive to changes in income and therefore the spending 
effect on health.  At the macro level, spending restrictions are set through a budget 
process for which individuals are not directly sensitive.  Because of those reasons, 
different results may be obtained at different levels of analysis.   
  However, the simple fact that that an elasticity does or does not exceed unity only 
means that as income increases, the increase in health care spending will be relatively 
higher than the increase in income.  As such, a legitimate role in the financing of 
health care cannot be based on whether a good is considered a luxury good or not in 
the economic sense.   
   The empirical results from this study do indicate that an increase of 10 percent of 
government share of total health expenditures is likely to decrease total health 
expenditures between 1.4 and 3.3 percent.   
      From the analysis, all estimates are negatively and except for one significantly 
related to the dependent variable is thought provoking. One possible reason why 
publicly financed health care may reduce expenditures is lower administrative costs.  
All countries that have statutory health insurance also have standardized levels of 
covered care for almost the whole population.  The financial resources are generated 
directly through taxes and/or contributions from employers and/or employees and, are 
then pooled on one account.  From that account, government either pays providers 
directly as is the case in single payer systems or, transfers the money to social 
insurances in third payer systems that are responsible for reimbursing covered health 
services.   
      Public and private insurance schemes have administrative costs caused by 
processing claims.  Commercial health insurances are more likely to have higher 
administrative costs that are caused by rating systems and premium structures that 
have to be developed and sometimes tailored to the purchasers’ preferences. There are 
sales and marketing costs to sell the insurance in a competitive market as well.   
Finally, there are the costs of complying with government regulation. (Pauly et al., 
1991, 1999, 2001; Thorpe, 1992)   
   Indeed, comparisons between countries show that in the United States administrative 
costs of health insurance are higher than in any other country (Himmelstein & 
Woolhandler, 2003; Reinhardt et al., 2004; Woolhandler et al., 2003; Woolhandler & 
Himmelstein, 2002).  In addition, a study on voluntary private insurance in the 
European Union showed that administrative costs of private insurance schemes are 
higher than their public counterparts (Colombo & Tapay, 2004; Mossialos & 
Thomson, 2002). 
   If there is a legitimate role for government in financing health care, the next question 
then, is whether the private sector has a role to play in a health care system.   The 
results from this analysis support a role for private entities.  The health system 
variable that is indicative of public predominance in a health care system is assumed 
to capture also the public provision of health services.  The results show that the 
presence of an NHS is an expenditure increasing institutional arrangement in the 
health care system if the assumption mentioned above holds strong.  This supports the 
public choice theory that states that public providers show monopolistic behavior 
causing inefficiencies, which is supported by results from research in two areas on the 
efficiency of health care providers.  
  9      First, waiting times is one manifestation of the inefficiency of public providers.   
Several studies have looked at differences between countries for referral time lags 
(Fleming et al., 1992) and waiting times for different surgical procedures. (Blendon et 
al. 2002; Carroll et al., 1995; Siciliani & Hurst, 2004)  Results show that in countries 
with public provision of medical care referral and waiting times are longer.   
      Second, empirical studies on hospitals have found that in NHS health systems 
hospitals behave as bureaucracies.  This resulted in budget maximizing behavior as 
well as misallocation of resources that on its turn resulted in overutilization of supplies 
and overinvestment in equipment leading to excess capacity.  (Rodriguez et al., 2004; 
Spicer, 1982) 
    With respect to pharmaceutical expenditures, the results support the substitution 
theory that argues that drugs can have an expenditure lowering effect because it has 
the potential to prevent more costly medical care later on.  An increase of 10 percent 
in pharmaceutical expenditure can reduce health expenditures between .8 and 1.5 
percent.   
   Over the years, empirical research predominantly focusing on elderly and welfare 
recipients has found evidence for this substitution theory (Poisal et al., 1999; Thomas 
et al., 2001). Studies in the United States show that limiting reimbursable medication 
has increased institutionalization among elderly covered by Medicaid (Soumerai et al., 
1991).  Similarly, HMO enrollees who were subject to pharmaceutical capitation had 
higher total health costs than those not subjected to capitation (Popovian et al., 1999). 
In addition, pharmaceutical cost increases for the treatment of schizophrenia was 
lower than cost increases of other medical services for treating the disease.  Finally, 
Lichtenberg (1996) found that hospitalization and surgical procedures was inversely 
related to number of prescribed drugs and that newer drugs were able to reduce-non 
pharmaceutical expenditures (Lichtenberg, 2000). 
  Unlike most comparative multivariate analyses, this analysis has rather robust 
estimates in the expected direction with respect to the impact of an ageing 
population on total health expenditure.  Urbanization is also positively related 





Important conclusions can be drawn from this study.  From an institutional 
perspective, the role of government with respect to financing of the health care system 
confirms most of the previous research.  An increased involvement of government in 
financing medical care can reduce total health expenditures because economies of 
scale.  However, the delivery of medical care may not be ideal when provided by a 
public provider.  In other words and based on the robust findings of this study, a 
publicly financed health care system with privately provided medical care seems to be 
preferable over any other arrangement of provision and delivery of medical care.   
Next, unlike most previous studies that attempted to identify the impact of 
demographic changes and their effects on national health expenditures, the results of 
this study confirms the even intuitively increasing effects of an ageing population on 
total health expenditures. Finally yet importantly, the impact of  pharmaceutical 
proportional expenditure on total health expenditure may have expenditure saving 
effects on health expenditures.  This study confirms at an aggregate level the 
substitution theory that is empirically supported by some meso and micro research.   
Given these findings, further research should focus on the respective role of the public 
and  private sector with respect to the delivery and financing of medical care as well as 
  10 the impact of pharmaceutical expenditures on total health expenditures within the 
context of an ageing population. 
  While the robustness of model across different samples is rather strong, endogeneity 
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Figure 1.  Per Capita Pharmaceutical Expenditures (1970 – 2000). 
                                                 
1 The typology code is the same as in Gerdtham et al. (1994, 1998 and 2003).  NHS countries 
are Denmark, Greece (since 1983), Iceland, Ireland, Italy (since 1979), New Zealand, Norway, 
Portugal (since 1978), Spain (since 1984), Sweden and the United Kingdom.  Non NHS 
countries are Australia, Austria, Canada, Germany, Greece (before 1983), Italy (before 1979), 
Japan, the Netherlands, Portugal  (before 1978), Spain (before 1984).  The United States is the 
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Figure 2.  Percent of Pharmaceutical Expenditures by Health Care System 




Table 1.  Per Capita Expenditures ($ PPP) on Pharmaceuticals by Decade 
(1970 – 2000).  
  1970 1980 1990 2000 
NHS System      
Denmark -  50  109  208 
Finland 20  54  122  264 
Iceland 22  92  216  - 
Ireland 22  49  88  191 
New Zealand  -  54  129  - 
Norway 10  55  98  - 
Sweden 18  55  120  305 
United Kingdom  21  57  132  - 
Average 18.8  58.3  126.8  242.0 
      
Non NHS System      
Australia -  53  117  292 
Austria  - - - - 
Canada 29  60  192  404 
Germany 36  110  228  379 
Japan -  111  232  315 
Netherlands -  53  128  237 
Average 32.5  74.3  179.0  358.3 
      
Entrepreneurial System      
United States  43  96  251  541 
      
Grand Average  31.4  76.2  185.6  380.4 
      
Source: OECD 2003 
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Table 2.  Results for Multi-Collinearity Tests. 
  Unimputed Unimputed Imputed   Imputed  
     No Us     No US 
GDP                             tol  0.7 0.7 0.63 0.64 
vif  1.42 1.41 1.56 1.55 
Public Share                tol  0.57 0.51 0.6 0.51 
vif 1.72 1.95 1.66 1.93 
NHS                             tol  0.6 0.62 0.66 0.69 
vif 1.66 1.59 1.5 1.43 
Pharma Share             tol  0.89 0.82 0.93 0.86 
vif 1.11 1.2 1.07 1.16 
Age 65+                       tol  0.75 0.77 0.72 0.74 
vif 1.32 1.29 1.37 1.34 
Urbanization               tol  0.59 0.51 0.63 0.54 
vif 1.67 1.93 1.57 1.85 
 
Table 3.  Test Results for Heteroscedasticity, Serial Correlation and Fixed 
Effects. 















a ≤ .01; 
b ≤ .05; 
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Table 4.  LSDV Estimates for the Different Samples. 
  Unimputed Unimputed  Imputed    Imputed  
      No US      No US 
Intercept  -0.18 -1.06 -0.41 
    -1.22 
c  
t  -0.26 -1.55 -0.6 -1.8 
GDP  0.56 
a 0.63 
a 0.6 
a   0.67 
a
t  10.1 11.61 10.45 12.08 
Public Share  -0.06  -0.26 
a   -0.14 
c   -0.33 
a  
t  -0.77 -3 -1.7 -3.29 
NHS  0.07 
b   0.08 
a  0.1 
c  0.09 
a  
t  2.07 2.47 3.29 3.4 
Pharma Share  -0.15 




t  -5.28 -4.41 -4.16 -3.4 
Age 65+  0.18 
a   0.21 
a   0.14 
a   0.18 
a  
t  3.35 3.93 2.6 3.45 
Urbanization  0.63 
a   0.63 
a  0.66 
a   0.65 
a  
t  9.06 9.54 5.99 9.29 





Observation  464 433 485 454 
N  589 558 589 558 
Percent missing  21.22 22.40 17.66 18.64 
a ≤ .01; 
b ≤ .05; 
c ≤ .1           
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14
th IRISS-C/I call for research proposals supported by the European Commission under the 
Transnational Access to major Research Infrastructures contract HPRI-CT-2001-00128 hosted by 
CEPS/INSTEAD, Differdange (Luxembourg). 
 
 
CEPS/INSTEAD announces its 14th call for research proposals under the IRISS project. 
CEPS/INSTEAD has been recognised as a Major Research Infrastructure under the European 
programme “Improving Human Potential and the Socio-economic Knowledge Base” under 
which IRISS research grants are offered. The aim of IRISS project is to foster access to 
information and mobility of European researchers in the socio-economic sciences by 
offering access to the local research facilities and archive of data. 
 
WHAT IS OFFERED 
Since 1998, the IRISS-C/I fellowships offer European researchers (both junior and senior) 
the opportunity to spend time carrying out their own research using the 
CEPS/INSTEAD infrastructure. The grants cover travel expenses and on-site 
accommodation, and include a stipend of 30 EUR/day for living expenses. The duration 
of IRISS-C/I visits may vary between 2 to 12 weeks, depending on the nature of the 
research project. 
During their stay, visitors are granted free access to the CEPS/INSTEAD archive of micro-
data (including the European Community Household Panel and the Panel Comparability 
(PACO) project data) and to the relevant data documentation. They are assigned an office 
(shared or single) and have access to a personal computer for office applications (i.e. word-
processing, E-Mail...) and to a powerful computation server that acts as host for the data 
archive and supports an array of commercial statistical software packages including Stata 
8.1, SPSS 11, SAS 8, Limdep 7.0, Matlab 6, as well as open-source solutions including R and 
TDA. 
Towards the end of their stay, IRISS-C/I fellows are invited to present their research results 
at a CEPS/INSTEAD seminar. In addition, they may make a brief presentation of their 
proposed research project at the start of their IRISS-C/I fellowship (e.g., to discuss 
methodology and data issues related to the proposed project), if they so desire.  
IRISS Working Papers
The IRISS Working Paper Series has been created in 1999 to ensure a timely dissemination of the research
outcome from the IRISS-C/I programme. They are meant to stimulate discussion and feedback. The
working papers are contributed both by CEPS/INSTEAD resident staff and by visiting researchers.
The ten most recent papers
Verbelen B., ‘Is Taking a Pill a Day Good for Health Expenditures? Evidence from a Cross Section Time
Series Analysis of 19 OECD Countries from 1970 2000.’, IRISS WP 2006-01, May 2006.
Kwiatkowska-Ciotucha D. & Zaluska U., ‘Job Satisfaction as an Assessment Criterion of Labor Market Policy
Efﬁciency. Lesson for Poland from International Experience’, IRISS WP 2005-04, May 2005.
Heffernan C., ‘Gender, Cohabitation and Martial Dissolution: Are changes in Irish family composition typi-
cal of European countries?’, IRISS WP 2005-03, March 2005.
Voynov I., ‘Household Income Composition and Household Goods’, IRISS WP 2005-02, March 2005.
Hildebrand V. & Van Kerm P ., ‘Income inequality and self-rated health status: Evidence from the European
Community Household Panel’, IRISS WP 2005-01, January 2005.
Yu K., Van Kerm P . & Zhang J., ‘Bayesian quantile regression: An application to the wage distribution in
1990s Britain’, IRISS WP 2004-10, August 2004.
Prez-Mayo J., ‘Consistent poverty dynamics in Spain’, IRISS WP 2004-09, May 2004.
Warren T., ‘Operationalising ’breadwinning’ work: gender and work in 21st century Europe’, IRISS WP 2004-
08, May 2004.
Jenkins S. & Van Kerm P ., ‘Accounting for income distribution trends: A density function decomposition
approach’, IRISS WP 2004-07, April 2004.
Maleshkov H., ‘Social and economic circumstances of sex differentials in poor health of elderly popula-
tion’, IRISS WP 2004-06, April 2004.
Electronic versions
Electronic versions of all IRISS Working Papers are available for download at
http://www.ceps.lu/iriss/wps.cfm
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